Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Pioglitazone Compared to a Combination Therapy With Ramipril and to a Ramipril Monotherapy on Low Grade Inflammation and Vascular Function in Patients With Increased Cardiovascular Risk and an Activated Inflammation. A Randomized Double-Blinded Phase II Study.

Next Previous
Trial Profile

Effect of Pioglitazone Compared to a Combination Therapy With Ramipril and to a Ramipril Monotherapy on Low Grade Inflammation and Vascular Function in Patients With Increased Cardiovascular Risk and an Activated Inflammation. A Randomized Double-Blinded Phase II Study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pioglitazone (Primary) ; Ramipril
  • Indications Hypertension; Insulin resistance
  • Focus Pharmacodynamics
  • Acronyms PIOace
  • Sponsors Takeda Pharma

Most Recent Events

  • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2006-004028-35).
  • 22 Oct 2009 Results presented at the 20th World Diabetes Congress.
  • 01 Oct 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top